Ground Swell Capital LLC purchased a new position in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 6,599 shares of the company’s stock, valued at approximately $564,000. Mirum Pharmaceuticals accounts for approximately 1.3% of Ground Swell Capital LLC’s investment portfolio, making the stock its 14th largest holding.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in shares of Mirum Pharmaceuticals in the 2nd quarter valued at approximately $513,945,000. Secure Asset Management LLC acquired a new position in shares of Mirum Pharmaceuticals in the 3rd quarter worth approximately $4,466,000. Man Group plc acquired a new position in shares of Mirum Pharmaceuticals in the 2nd quarter worth approximately $4,353,000. Jupiter Topco LLC acquired a new position in shares of Mirum Pharmaceuticals in the 2nd quarter worth approximately $691,672,000. Finally, Rice Hall James & Associates LLC bought a new position in shares of Mirum Pharmaceuticals during the 2nd quarter worth approximately $12,956,000.
Mirum Pharmaceuticals Price Performance
NASDAQ:MIRM traded up $0.66 on Friday, reaching $93.99. The stock had a trading volume of 331,049 shares, compared to its average volume of 616,358. The company has a market capitalization of $6.14 billion, a P/E ratio of -6.08 and a beta of 0.75. Mirum Pharmaceuticals, Inc. has a 1-year low of $63.23 and a 1-year high of $130.00. The company has a quick ratio of 1.98, a current ratio of 2.07 and a debt-to-equity ratio of 1.28. The stock has a fifty day moving average price of $88.79 and a 200-day moving average price of $98.41.
Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) last issued its quarterly earnings data on Tuesday, November 3rd. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.38). The firm had revenue of $185.72 million for the quarter, compared to the consensus estimate of $178.07 million. Mirum Pharmaceuticals had a negative return on equity of 97.25% and a negative net margin of 134.75%. Mirum Pharmaceuticals’s quarterly revenue was up 39.6% compared to the same quarter last year. During the same period in the prior year, the company posted $0.05 earnings per share. Research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.47 EPS for the current year.
Insider Activity
In other news, SVP Jolanda Howe sold 40,000 shares of Mirum Pharmaceuticals stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $100.00, for a total value of $4,000,000.00. Following the completion of the transaction, the senior vice president owned 1,274 shares in the company, valued at approximately $127,400. The trade was a 96.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Laura Brege sold 14,167 shares of the business’s stock in a transaction that occurred on Wednesday, November 11th. The stock was sold at an average price of $94.21, for a total value of $1,334,673.07. Following the completion of the transaction, the director directly owned 15,703 shares in the company, valued at $1,479,379.63. The trade was a 47.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 104,825 shares of company stock worth $10,160,873. Insiders own 8.32% of the company’s stock.
Analyst Upgrades and Downgrades
Several brokerages recently commented on MIRM. Leerink Partners decreased their price target on Mirum Pharmaceuticals from $154.00 to $140.00 and set an “outperform” rating on the stock in a research note on Thursday, November 5th. Citigroup upped their price target on Mirum Pharmaceuticals from $184.00 to $194.00 and gave the company a “buy” rating in a research report on Wednesday. Cantor Fitzgerald increased their price objective on Mirum Pharmaceuticals from $155.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 4th. Citizens Jmp increased their price objective on Mirum Pharmaceuticals from $144.00 to $167.00 and gave the stock a “market outperform” rating in a research note on Wednesday, November 4th. Finally, Weiss Ratings cut Mirum Pharmaceuticals from a “sell (d)” rating to a “sell (d-)” rating in a report on Thursday, October 22nd. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $155.56.
Check Out Our Latest Report on Mirum Pharmaceuticals
Mirum Pharmaceuticals Profile
Mirum Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing treatments for rare liver and other serious diseases. Founded in 2018, the company works on therapies for conditions with limited treatment options. Its commercial products include Livmarli (maralixibat), an oral treatment for cholestatic pruritus associated with Alagille syndrome and, in the United States, progressive familial intrahepatic cholestasis. Mirum also markets Cholbam (cholic acid) for certain bile acid synthesis disorders and Chenodal (chenodiol) for cerebrotendinous xanthomatosis.
Further Reading
- Five stocks we like better than Mirum Pharmaceuticals
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding MIRM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Free Report).
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
